The evaluation of the functional repercussions of mutations in cancer-pathway-associated genes showed that mutations occurring in the CDX2-suppressed group were potentially pathogenic in similar percentages, or for some genes, in higher percentages than mutations of the same genes in the entire TCGA colorectal cancer cohort (Figure 7 and Table 3). This evidence concerns the gene CDX2 and colorectal cancer.